Literature DB >> 9605979

Use of lytic bacteriophage for control of experimental Escherichia coli septicemia and meningitis in chickens and calves.

P Barrow1, M Lovell, A Berchieri.   

Abstract

A lytic bacteriophage, which was previously isolated from sewage and which attaches to the K1 capsular antigen, has been used to prevent septicemia and a meningitis-like infection in chickens caused by a K1+ bacteremic strain of Escherichia coli. Protection was obtained even when administration of the phage was delayed until signs of disease appeared. The phage was able to multiply in the blood. In newly borne colostrum-deprived calves given the E. coli orally, intramuscular inoculation of phage delayed appearance of the bacterium in the blood and lengthened life span. With some provisos there is considerable potential for this approach to bacterial-disease therapy.

Entities:  

Mesh:

Year:  1998        PMID: 9605979      PMCID: PMC104512          DOI: 10.1128/CDLI.5.3.294-298.1998

Source DB:  PubMed          Journal:  Clin Diagn Lab Immunol        ISSN: 1071-412X


  29 in total

1.  Translocation of bacteriophage across the intestinal wall of the rat.

Authors:  G J HILDEBRAND; H WOLOCHOW
Journal:  Proc Soc Exp Biol Med       Date:  1962-01

2.  The Rôle of the Twort-d'Herelle Phenomenon in Epidemics of Mouse-Typhoid.

Authors:  W W Topley; J Wilson; E R Lewis
Journal:  J Hyg (Lond)       Date:  1925-07

3.  Transmissible pathogenic characteristics of invasive strains of Escherichia coli.

Authors:  H W Smith
Journal:  J Am Vet Med Assoc       Date:  1978-09-01       Impact factor: 1.936

4.  The effect of plasmid-determined and other characteristics on the survival of Escherichia coli in the alimentary tract of two human beings.

Authors:  H W Smith; M B Huggins
Journal:  J Gen Microbiol       Date:  1978-12

5.  Treatment of experimental Escherichia coli infection in mice with colicine V.

Authors:  H W Smith; M B Huggins
Journal:  J Med Microbiol       Date:  1977-11       Impact factor: 2.472

6.  Further observations on the association of the colicine V plasmid of Escherichia coli with pathogenicity and with survival in the alimentary tract.

Authors:  H W Smith; M B Huggins
Journal:  J Gen Microbiol       Date:  1976-02

7.  The experimental infection of chickens with mixtures of infectious bronchitis virus and Escherichia coli.

Authors:  H W Smith; J K Cook; Z E Parsell
Journal:  J Gen Virol       Date:  1985-04       Impact factor: 3.891

8.  The control of experimental Escherichia coli diarrhoea in calves by means of bacteriophages.

Authors:  H W Smith; M B Huggins; K M Shaw
Journal:  J Gen Microbiol       Date:  1987-05

9.  The activity in the chicken alimentary tract of bacteriophages lytic for Salmonella typhimurium.

Authors:  A Berchieri; M A Lovell; P A Barrow
Journal:  Res Microbiol       Date:  1991-06       Impact factor: 3.992

10.  Epidemiology of Escherichia coli K1 in healthy and diseased newborns.

Authors:  L D Sarff; G H McCracken; M S Schiffer; M P Glode; J B Robbins; I Orskov; F Orskov
Journal:  Lancet       Date:  1975-05-17       Impact factor: 79.321

View more
  72 in total

Review 1.  Pharmacokinetic principles of bacteriophage therapy.

Authors:  Robert J H Payne; Vincent A A Jansen
Journal:  Clin Pharmacokinet       Date:  2003       Impact factor: 6.447

2.  Reviving Phage Therapy for the Treatment of Cholera.

Authors:  Sudhakar Bhandare; Joan Colom; Abiyad Baig; Jenny M Ritchie; Habib Bukhari; Muhammad A Shah; Banwarilal L Sarkar; Jingliang Su; Brendan Wren; Paul Barrow; Robert J Atterbury
Journal:  J Infect Dis       Date:  2019-02-15       Impact factor: 5.226

3.  Efficacy of bacteriophage therapy against gut-derived sepsis caused by Pseudomonas aeruginosa in mice.

Authors:  Ryohei Watanabe; Tetsuya Matsumoto; Go Sano; Yoshikazu Ishii; Kazuhiro Tateda; Yoshinobu Sumiyama; Jumpei Uchiyama; Shingo Sakurai; Shigenobu Matsuzaki; Shosuke Imai; Keizo Yamaguchi
Journal:  Antimicrob Agents Chemother       Date:  2006-11-20       Impact factor: 5.191

4.  Genome sequencing and analysis of an Escherichia coli phage vB_EcoM-ep3 with a novel lysin, Lysep3.

Authors:  Meng Lv; Shuang Wang; Guangmou Yan; Changjiang Sun; Xin Feng; Jingmin Gu; Wenyu Han; Liancheng Lei
Journal:  Virus Genes       Date:  2015-04-05       Impact factor: 2.332

5.  Experimental bacteriophage protection against Staphylococcus aureus abscesses in a rabbit model.

Authors:  Quintin F Wills; Claire Kerrigan; James S Soothill
Journal:  Antimicrob Agents Chemother       Date:  2005-03       Impact factor: 5.191

6.  Isolation of Escherichia coli bacteriophages from the stool of pediatric diarrhea patients in Bangladesh.

Authors:  Sandra Chibani-Chennoufi; Josette Sidoti; Anne Bruttin; Marie-Lise Dillmann; Elizabeth Kutter; Firdausi Qadri; Shafiqul Alam Sarker; Harald Brüssow
Journal:  J Bacteriol       Date:  2004-12       Impact factor: 3.490

7.  Phage Therapy - Everything Old is New Again.

Authors:  Andrew M Kropinski
Journal:  Can J Infect Dis Med Microbiol       Date:  2006-09       Impact factor: 2.471

Review 8.  Phage therapy and photodynamic therapy: low environmental impact approaches to inactivate microorganisms in fish farming plants.

Authors:  Adelaide Almeida; Angela Cunha; Newton C M Gomes; Eliana Alves; Liliana Costa; Maria A F Faustino
Journal:  Mar Drugs       Date:  2009-07-30       Impact factor: 5.118

9.  The in vivo efficacy of two administration routes of a phage cocktail to reduce numbers of Campylobacter coli and Campylobacter jejuni in chickens.

Authors:  Carla M Carvalho; Ben W Gannon; Deborah E Halfhide; Silvio B Santos; Christine M Hayes; John M Roe; Joana Azeredo
Journal:  BMC Microbiol       Date:  2010-09-01       Impact factor: 3.605

10.  Orally administered P22 phage tailspike protein reduces salmonella colonization in chickens: prospects of a novel therapy against bacterial infections.

Authors:  Shakeeba Waseh; Pejman Hanifi-Moghaddam; Russell Coleman; Michael Masotti; Shannon Ryan; Mary Foss; Roger MacKenzie; Matthew Henry; Christine M Szymanski; Jamshid Tanha
Journal:  PLoS One       Date:  2010-11-22       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.